Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.70 |
| ▸ | ACHE | P22303 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanthine SCHEMBL160198 | 0.83 | GDA (0.82) | GDAACHEALDH1A1ABL1RIN1 | |
| Xanthine SCHEMBL29669592 | 0.83 | GDA (1.00) | GDAACHEALDH1A1ABL1RIN1 | |
| Xanthine SCHEMBL4965 | 0.83 | GDA (1.00) | GDAACHEALDH1A1ABL1RIN1 | |
| Xanthine SCHEMBL2352524 | 0.83 | GDA (1.00) | GDAACHEALDH1A1ABL1RIN1 | |
| Xanthine SCHEMBL4295220 | 0.81 | GDA (0.79) | GDAACHEALDH1A1ABL1RIN1 | |
| Xanthine SCHEMBL7044227 | 0.81 | GDA (0.96) | GDAACHEALDH1A1ABL1RIN1 | |
| Xanthine SCHEMBL2454001 | 0.81 | GDA (0.96) | GDAACHEALDH1A1ABL1RIN1 | |
| Xanthine SCHEMBL7849418 | 0.81 | GDA (0.96) | GDAACHEALDH1A1ABL1RIN1 | |
| Xanthine SCHEMBL31488667 | 0.81 | GDA (0.96) | GDAACHEALDH1A1ABL1RIN1 | |
| Xanthine SCHEMBL1507586 | 0.81 | GDA (0.96) | GDAACHEALDH1A1ABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3801538-B1 | TLR7 AGONISTS | PRIMMUNE THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | claimed |
| US-20250129077-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2025-04-24 | — | — | US | disclosed |
| US-20250122184-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4512816-A2 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-112533607-B | TLR7 agonists | 普利缪尼治疗学股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-3801538-B1 | TLR7 AGONISTS | PRIMMUNE THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-12037335-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220428-A1 | COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| CN-116507724-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-4065155-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20220098198-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
| WO-2022047279-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2017060488-A1 | NEW TRPA1 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2017-04-13 | — | — | WO | disclosed |
| WO-2012016145-A2 | MITOCHONDRIAL APOPTOSIS-INDUCED INFLAMMATION | CEDARS-SINAI MEDICAL CENTER (US) | 2012-02-02 | — | — | WO | disclosed |
| US-7666977-B2 | Poly(carbonate-co-urea) copolymers and melt transesterification method of preparing these copolymers | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2010-02-23 | — | — | US | disclosed |
| US-7557175-B2 | Poly(carbonate-co-urea) copolymers and melt transesterification method of preparing these copolymers | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2009-07-07 | — | — | US | disclosed |
| WO-2008136841-A1 | POLY(CARBONATE-CO-UREA) COPOLYMERS AND MELT TRANSESTERIFICATION METHOD OF PREPARING THESE COPOLYMERS | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2008-11-13 | — | — | WO | disclosed |
| US-20080275206-A1 | POLY(CARBONATE-CO-UREA) COPOLYMERS AND MELT TRANSESTERIFICATION METHOD OF PREPARING THESE COPOLYMERS | GENERAL ELECTRIC COMPANY (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080275209-A1 | POLY(CARBONATE-CO-UREA) COPOLYMERS AND MELT TRANSESTERIFICATION METHOD OF PREPARING THESE COPOLYMERS | GENERAL ELECTRIC COMPANY (US) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037335-B2 | Substituted purines as TLR7 agonists | TLR7, TLR9, TLR1 | GDA 140/4885ACHE 4829/4885ALDH1A1 934/4885 |
| US-20250122184-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | GDA 4649/4885ACHE 851/4885ALDH1A1 721/4885 |
| US-20220098198-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | TLR7, TLR9, TLR1 | GDA 140/4885ACHE 4829/4885ALDH1A1 934/4885 |
| US-20250129077-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | TLR7, TLR9, TLR1 | GDA 140/4885ACHE 4829/4885ALDH1A1 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.